|
SGX Pharmaceuticals, Inc. - Company Profile Snapshot
| Company Profile: |
SGX Pharmaceuticals, Inc. |
| Ticker: |
SGXP |
| Exchanges: |
NAS |
| 2007 Sales: |
34,739,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
123 |
Business Description
SGX Pharmaceuticals, Inc.. The Group's principal activety is to discover, develop & innovative cancer therapeutics. It develops Troxatyl, a novel compound which is currently in a pivotal Phase II/III clinical trial for the third-line treatment of Acute Myelogenous Leukemia, or AML, a blood cancer. Third-line treatment refers to the treatment of patients who have already received two regimens of chemotherapy with the goal of remission. it also developing an internal oncology product pipeline and lead compounds for multiple partners through the application of its proprietary fragment-based drug discovery platform, Fragments of Active Structures. It operates only in United States.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
